Matthew Goetz, M.D., Named ACCRU Vice Chair

Matthew Goetz, M.D., Named ACCRU Vice Chair Matthew Goetz, M.D., Named ACCRU Vice Chair


Podcast About Our Clinical Trials

News About Our Clinical Trials

ACCRU Transformative Research

Matthew Goetz, M.D., Named ACCRU Vice Chair

ACCRU News & Releases – May 21, 2019

Academic and Community Cancer Research United (ACCRU) is pleased to announce that Matthew Goetz, M.D., has been named vice chair. Dr. Goetz replaces Charles Loprinzi, M.D., who has served as vice chair since 2011.

Dr. Goetz’s research focuses on estrogen receptor positive breast cancer and the development of novel therapeutics for endocrine resistant breast cancer. In his research, Dr. Goetz has explored the pharmacogenetics of tamoxifen, and has collaborated with the National Cancer Institute (NCI) to develop the tamoxifen metabolite Z-Endoxifen, for patients with endocrine resistant breast cancer.

Dr. Goetz is research chair of the Mayo Clinic Cancer Center Breast Disease Group and director of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE). Additionally, he is co-leader of the Mayo Clinic Cancer Center Women’s Cancer Program. Nationally, he is a member of the NCI Breast Cancer Steering Committee.

ACCRU thanks Dr. Loprinzi for his leadership, mentorship and dedication. Dr. Loprinzi will remain on the ACCRU leadership team as Symptom Control Program Lead.

ACCRU is a collaborative clinical research network of academic and community-based cancer centers with a goal to prevent cancer, cure cancer, and attenuate cancer-related symptoms. The ACCRU Research Coordinating Center is based at Mayo Clinic Cancer Center.

For more information contact the ACCRU Operations Office at »

Go to Top